Abstract Purpose: In preclinical models, calcitriol and the tyrosine kinase inhibitor gefitinib are synergistic and modulate extracellular signal-regulated kinase (Erk) and Akt pathways. Therefore, we conducted a phase I study of calcitriol and gefitinib to determine the maximum tolerated dose (MTD) of this combination. Experimental Design: Calcitriol was given i.v. over 1 h on weeks 1, 3, and weekly thereafter. Gefitinib was given at a fixed oral daily dose of 250 mg starting at week 2 (day 8). Escalation occurred in cohorts of three patients until the MTD was defined. Pharmacokinetic studies were done for calcitriol and gefitinib. Serial skin biopsies were done to investigate epidermal growth factor receptor (EGFR) pathway pharmacodynamic interactions. Results: Thirty-two patients were treated. Dose-limiting hypercalcemia was noted in two of four patients receiving 96 Ag/wk of calcitriol. One of seven patients developed dose-limiting hypercalcemia at the MTD 74 Ag/wk calcitriol dose level.The relationship between calcitriol dose and peak serum calcitriol (C max ) and systemic exposure (AUC) was linear. Mean (FSD) serum calcitriol C max at the MTD was 6.68 F 1.42 ng/mL. Gefitinib treatment inhibited EGFR, Akt, and Erk phosphorylation in the skin. Calcitriol did not have consistent effects on skin EGFR or its downstream elements. The combination of gefitinib and calcitriol did not modulate tumor EGFR pathway in patients with serial tumor biopsies. Conclusions: High doses of weekly i.v. calcitriol can be administered safely in combination with gefitinib. Calcitriol concentrations achieved at the MTD 74 Ag calcitriol exceed in vivo concentrations associated with antitumor activity in preclinical models.
schedule of (i.v.) calcitriol was chosen for patient convenience and to minimize risk of hypercalcemia.
Secondary end points included the evaluation of calcitriol and gefitinib pharmacokinetics and to investigate the possibility of pharmacokinetic interaction between these agents. Serial skin biopsies were done before treatment, after calcitriol treatment, after gefitinib treatment, and after the combination of gefitinib and calcitriol to explore the effects of these drugs and their combination on the EGFR pathway. Skin biopsies were scheduled around 8 h from calcitriol and/or gefitinib dosing. Biopsy timing was selected based on preclinical data supporting maximum EGFR phosphorylation inhibition after 8 h from treatment with a calcitriol analogue (15) .
Materials and Methods
Patient criteria. Patients with histologically or cytologically confirmed solid tumors that were metastatic or unresectable and for which standard curative or palliative measures did not exist were eligible for the trial. The last chemotherapeutic or radiation treatment was at least 4 weeks (6 weeks for nitrosoureas or mitomycin C) before trial enrollment. Other criteria included age z18 years, Eastern Cooperative Oncology Group performance status V2, estimated life expectancy >12 weeks, no central nervous system involvement, adequate bone marrow function (neutrophils z1,500/AL, hemoglobin z8.0 g/dL, and platelets z100,000/AL), adequate hepatic function (serum bilirubin V upper limit of the reference range; serum aspartate aminotransferase and alanine aminotransferase V2.5 Â upper limit of the reference range), and adequate renal function (creatinine V1.5 upper limit of the reference range or creatinine clearance z60 mL/min). The study excluded patients unable to receive oral medications; patients with brain metastases; patients with history of hypercalcemia or genitourinary stones; patients on digoxin, thiazide, calcium supplements, and supraphysiologic doses of glucocorticoids (exceeding the equivalent of 15 mg of hydrocortisone per day); and patients with prior allergic reaction to calcitriol or gefitinib. HIV-positive patients were not eligible because of possible pharmacokinetic interaction with antiretroviral drugs. Patients with reproductive potential had to agree to use adequate contraception before study entry and for the duration of study participation. The study and consent form was approved by the Institutional Scientific and Review Committee and the Institutional Review Board before its activation. All patients provided signed informed consent before study entry. The study was conducted in accordance with the Good Clinical Practice Guidelines as issued by the International Conference on Harmonization and the Declaration of Helsinki.
Study design and treatment plan. Three patients were entered at each dose level. In the absence of dose-limiting toxicity (DLT), the next dose level was explored. If DLT was seen in one patient, three further patients were added at that dose level and, if no additional DLT was seen, escalation to the next dose level occurred. If at least two patients had DLT at a given dose level, accrual to that dose level was stopped; this was the maximally administered dose. Further patients were then added, as required, to the previous dose level (and if necessary to lower dose levels) to establish the highest dose at which less than two of six patients had DLT. This was the MTD.
Patients received calcitriol i.v. over 60 min once weekly except for week 2. Calcitriol (Calcijex) was supplied in 1 Ag vials by Abbott Laboratories (Abbott Park, IL). The first dose level of calcitriol was 10 Ag. Subsequent dose escalation levels were 15, 20, 26, 34, 44, 57, 74 , and 96 Ag/wk. No intrapatient escalation was allowed. Gefitinib (Iressa) was supplied by AstraZeneca (London, United Kingdom) in 250 mg tablets and was given once daily starting 1 week after the first dose of calcitriol (treatment schema; Fig. 1) .
A DLT was any of the following toxicities that were attributable to study treatment on cycle 1 (first 4 weeks of treatment): any grade 3 or 4 toxicity except for grade 3 anemia, any grade 2 or above hypercalcemia (corrected calcium >11.5 mg/dL) if confirmed on repeat blood draw (>72 h), any grade 2 or above hypercalcemia that is associated with serious hypercalcemic symptoms, any treatment interruption that lasts for >2 weeks that is related to treatment toxicity, sustained increase (>72 h) in creatinine to >2Â baseline and >2 g/dL, and clinical or radiological evidence of new genitourinary stones.
No dose modifications were allowed for gefitinib; however, treatment interruptions were allowed for periods not exceeding 2 weeks for grade 3 and above skin toxicity, grade 3 and above diarrhea, grade 3 and above nausea unrelated to hypercalcemia, and grade 4 neutropenia. In case of dose interruption secondary to toxicity, treatment was resumed upon improvement to grade 1 or less with the exception of neutropenia, in which case retreatment was allowed when the count exceeded 500 cells/mm 3 . No dose modifications were allowed for DLTs related to calcitriol, in which case patients had to be discontinued from study. No growth factors were allowed on the study with the exception of recombinant erythropoietin.
Clinical evaluation and follow-up. A complete medical history, physical examination, pregnancy test for women with reproductive potential, complete blood count, and comprehensive chemistry profile (electrolytes, blood urea nitrogen, creatinine, magnesium, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, bilirubin) were obtained within 1 week before treatment initiation. Baseline computed tomography scans of the chest, abdomen, and pelvis were obtained within 4 weeks before initiation of treatment. Complete blood count and comprehensive chemistry were repeated on a weekly basis. Calcium, phosphorous, and creatinine levels were measured before as well as 3 days after each calcitriol infusion. Medical history, physical examination, and toxicity assessment as per National Cancer Institute Common Toxicity Criteria 2.0 were done on the first day of the 1st and 3rd weeks of cycle 1 and on day 1 of week 1 of each subsequent cycle. Corrected calcium was used to grade hypercalcemia [corrected calcium = serum calcium + (4 À serum albumin) Â 0.8]. Computed tomography scans of chest, abdomen, and pelvis were repeated every two cycles (8 weeks) to assess response. Responses were categorized according to the Response Evaluation Criteria in Solid Tumors (21) .
Skin and tumor biopsies. Skin biopsy specimens (4-mm wide, 8-mm deep) were obtained from the suprascapular areas using a punch biopsy to the level of the s.c. tissue after local anesthesia with 1% lidocaine. Serial biopsies were obtained from the same regions (Fig. 1) . The first skin biopsy was obtained before treatment (baseline). The second Fig. 1 . Treatment schema. On cycle 1, calcitriol (black arrow) was given on days 1 and 15 and weekly thereafter. Gefitinib started on day 8. Skin biopsies (black cross) were done at baseline, after the first dose of calcitriol, after 7 d of gefitinib (day 14) , and after the combination calcitriol + gefitinib (day 15). Pharmacokinetics (black triangle) were done on days 1and 15 for calcitriol and on day 15 for gefitinib. On cycles 2 and beyond, calcitriol was administered weekly along with daily gefitinib. biopsy was obtained f6 to 8 h after the first calcitriol infusion (day 1) to determine the effects of calcitriol alone on the EGFR pathway. The third biopsy was obtained after 1 week of treatment with gefitinib (day 14) and before the second infusion of calcitriol to determine the effects of gefitinib alone on the EGFR pathway. The last skin biopsy was done 6 to 8 h after the second dose of calcitriol (day 15) to determine the effects of calcitriol and gefitinib combination on the EGFR pathway.
In selected consenting patients with easily accessible tumors, tumor biopsies were obtained before treatment and 6 to 8 h after the second dose of calcitriol to determine the effects of calcitriol and gefitinib combination on the tumor EGFR pathway.
Immunohistochemistry studies. Levels of EGFR, phosphorylated (p)EGFR, Erk, pErk, Akt, and pAkt in the skin and tumor biopsies were assayed by immunohistochemistry procedures using antibodies to EGFR (Zymed, San Francisco, CA), pEGFR (Calbiochem, San Diego, CA), Erk (Cell Signaling, Beverly, MA), pErk (Cell Signaling), Akt (Santa Cruz Biotechnology, Santa Cruz, CA), and pAkt (Cell Signaling). The methodology was previously described (22, 23) .
Immunohistochemistry analysis. The staining intensity was measured semiquantitatively by a researcher (J.D.B.) with extensive experience in this field. Each sample was scored from 0 (no staining), 1+ (weakly positive), 2+ (moderately positive), to 3+ (strongly positive) for EGFR, pEGFR, Erk, pErk, Akt, and pAkt.
Pharmacokinetics. Ten milliliters of blood were collected in a nonheparinized (red-top) tube at baseline; at 30 and 45 min; and at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, and 72 h after calcitriol infusion on days 1 and 15 of treatment for calcitriol pharmacokinetics. Pharmacokinetic sampling at dose <57 Ag/wk was up to 24 h; it was extended after a protocol amendment to 72 h for patients treated at 57, 74, and 96 Ag/wk calcitriol doses. Serum samples prepared immediately by a 10-min centrifugation at 2,000 Â g were batched and stored in 1 to 2 mL aliquots at À20jC until assayed for calcitriol levels. Serum calcitriol concentrations were determined using 1,25-dihydroxyvitamin On days 8 and 15, the 1st and 8th days of gefitinib administration, 4 mL of blood were collected at (0, 0.5, 1, 2, 4, 6, 8, and 24 h) into tubes containing lithium heparin anticoagulant. Trough levels were also obtained 1 week later (day 22). Within 30 to 60 min of collection, blood samples were centrifuged at 1,000 Â g for 10 min to provide plasma for evaluation of gefitinib levels. Plasma samples were stored at À20jC before analysis by high-performance liquid chromatography with tandem mass spectrometry. Analysis was done by Analytico Medinet B.V., AstraZeneca (Breda, the Netherlands), as previously described (24) . Plasma drug concentrations were used to determine whether steady state had been achieved and to provide a measure of exposure.
Results

Demographics. Between December 2003 and April 2005, 34
patients (32 evaluable) were entered on the study. Two patients never received treatment secondary to progressive disease and early withdrawal. Patient characteristics are detailed in Table 1 .
Treatment administration. Thirty-two patients received treatment on study. Nine dose levels were evaluated. The median number of cycles administered was 2 (8 weeks). Five patients received four or more cycles. All patients without DLT were able to receive all intended dosage on cycle 1.
Toxicity. All 32 treated patients were evaluated for toxicity. Nonhematologic toxicities are outlined in Table 2 .
Hematologic toxicity
The combination of calcitriol and gefitinib did not result in any significant bone marrow suppression. None of the patients treated on this study developed >grade 2 neutropenia or thrombocytopenia. Two patients developed grade 2 anemia on cycles 2 and beyond treatment. One patient developed grade 3 anemia during cycle 7 of treatment, which was attributed to chronic disease and anticoagulation therapy. One patient developed grade 4 anemia related to nonsteroidal antiinflammatory drug -induced gastrointestinal bleeding on cycle 4 of treatment.
Nonhematologic toxicity
Rash and gastrointestinal toxicities. The most common nonhematologic adverse events were rash, diarrhea, nausea, and vomiting. Twenty patients developed rash on study, none of which was grade 3 (13 patients grade 1; 7 patients grade 2). The rash typically developed in the first 3 weeks of treatment of gefitinib (cycle 1) and did not seem to worsen with continuation of treatment. Diarrhea occurred in 18 patients and was limited to grade 1 (13 patients) and grade 2 (5 patients); it was manageable in all patients with loperamide use. Nausea and vomiting were less common. Only four patients developed grade 2 nausea and vomiting during treatment. Rash and gastrointestinal toxicities are summarized in Table 2 .
Hypercalcemia. Hypercalcemia was limited to grade 1 (greater than the upper limit of the reference range to 11.5 mg/dL) in 12 patients on the first 7 dose levels (10-57 Ag). Seven patients (one patient was replaced because of early progression) were enrolled at the eight dose level of 74 Ag calcitriol per week: four patients developed grade 1, one grade 2 (>11.5 to 12.5 mg/dL), and one grade 3 hypercalcemia (>12.5 to 13.5 mg/dL). Four patients were enrolled at the ninth dose level of 96 Ag calcitriol per week: one patient developed grade 1 and two patients developed grade 2 hypercalcemia. The results are summarized in Table 3 .
The mean increase in cycle 1 calcium levels between days 1 and 4 of each calcitriol week (calcium D4-calcium D1) was more pronounced at the highest two dose levels investigated ( Fig. 2A) . The mean increase was higher than 2 mg/dL in three patients only: two patients at the 96 Ag calcitriol dose level and Other toxicities. Phosphorous and creatinine levels did not vary between day 4 and day 1 or between cycles, even at higher doses of calcitriol. One patient developed grade 3 corneal toxicity (abrasion) on cycle 4, which was attributed to gefitinib and resulted in treatment discontinuation.
DLT, MTD, and recommended dose. No DLTs were noted on dose levels 1 to 7. At dose level 8 (74 Ag/wk of calcitriol), no DLTs were noted in the first three patients and escalation proceeded to dose level 9 (96 Ag/wk). A total of four patients were enrolled at dose level 9, two of whom developed DLTs attributed to calcitriol and occurring within the first 3 days after the first infusion. Both DLTs consisted of symptomatic grade 2 hypercalcemia: corrected calcium of 11.7 mg/dL with hallucinations in one patient and corrected calcium of 12.4 mg/dL with ataxia in the second. Central nervous system toxicities were resolved within 24 to 48 h in both patients with resolution of hypercalcemia. Dose level 9 was declared a nontolerable dose level, and dose level 8 (calcitriol 74 Ag/wk) was expanded to a total of seven evaluable patients (one replaced before completing cycle 1 secondary to disease progression). One of seven patients at dose level 8 developed an asymptomatic grade 3 DLT hypercalcemia (corrected calcium of 13.4 mg/dL) on day 4 of week 4 of cycle 1. Dose level 8 was declared the MTD.
Antitumor activity. Thirty patients were evaluable for response. Two of the 32 treated patients were nonevaluable for response because they were taken off study secondary to DLT hypercalcemia. None of the patients had an objective response. Three patients had a confirmed disease stabilization lasting 8 months in two (penile cancer and prostate) and 4 months (prostate) in the third.
Pharmacokinetics
Calcitriol pharmacokinetics. There was a substantial interpatient variation in day 1 pretreatment serum calcitriol levels; the median (range) concentration was 39 pg/mL (13-145 pg/ mL). Day 1 concentration over time plots showed substantial interpatient variability in serum calcitriol levels achieved at all dose levels. Figure 2B shows concentration over time plots at two low calcitriol doses (10 and 20 Ag), the MTD of 74 Ag, and 96 Ag (the highest calcitriol doses administered). Peak serum levels were observed half way through the calcitriol infusion and started decreasing immediately after the infusion. Calcitriol was cleared from serum in a biexponential fashion, remained elevated 24 and 48 h posttreatment, and were within the pretreatment range at 72 h. A summary of the serum calcitriol pharmacokinetic variables at all calcitriol dose levels is shown in Table 4 . C max serum calcitriol concentrations in the range of 10 nmol/L (z4.0 ng/mL) were achieved in patients treated with at 74 and 96 Ag calcitriol doses. Figure 2C shows that the relationship between calcitriol dose administered and either C max or AUC 0-24 h achieved was linear. Day 15 repeat pharmacokinetic studies after administration of calcitriol with gefitinib showed no effect on serum calcitriol concentration-time profiles. Figure 2D shows the effect of gefitinib on serum calcitriol concentration over time plots at 10 Ag (lowest dose), 44 Ag (intermediate dose), and 74 Ag (the MTD of calcitriol). Gefitinib administration had no effect on serum calcitriol pharmacokinetic variables at all calcitriol dose levels (P > 0.05, data not shown).
Gefitinib pharmacokinetics. Intensive gefitinib pharmacokinetic sampling was done on the 1st and 8th day of gefitinib. A repeat trough level was also obtained 1 week later. Gefitinib pharmacokinetic results are summarized in Table 5 . Intensive gefitinib pharmacokinetic sampling on day 15 (day 8 of gefitinib) and trough levels from day 22 of cycle 1 (day 15 of gefitinib) were consistent with prior steady-state levels from prior studies using single-agent gefitinib at 250 mg/d on IDEAL 1 study (17). 5 Immunohistochemistry (skin and tumor). Skin biopsies were done (a) prestudy; (b) after 6 to 8 h from first calcitriol infusion; (c) on day 14, after 7 days of gefitinib (after being 2-week calcitriol-free); and (d) on day 15 after 6 to 8 h from second infusion of calcitriol (concurrently with gefitinib). Significant interpatient variability was noted in skin EGFR pathway staining for all tested variables (data not shown). In general, total EGFR, Erk, and Akt levels were unchanged with calcitriol, gefitinib, or combination therapy. Gefitinib alone (day 14 biopsy) decreased pEGFR, pErk, and pAkt staining. This effect on Akt was less obvious when calcitriol and gefitinib were given in combination (Fig. 3) . No definite effects of calcitriol on EGFR signaling could be confirmed; specifically, no pAkt effects could be delineated. Furthermore, no calcitriol doseeffect trends on EGFR pathway were detected.
Two patients (breast cancer and gastrointestinal stromal tumor) treated at dose level 4 of calcitriol agreed to tumor biopsies at baseline and on day 15 of treatment to evaluate the effect of the combination calcitriol and gefitinib on intratumor EGFR pathway. In contrast to the inhibitory effects noted in the skin, no effects were noted with combination therapy on tumor EGFR, Erk, and Akt phosphorylation/activation.
Discussion
Calcitriol, 1,25-dihydroxyvitamin-D 3 , has antitumor and differentiating activities in preclinical models. Preclinical data indicate that antitumor activity is calcitriol concentration dependent-antitumor activity increases as concentrations are escalated from 1 to 100 nmol/L (25, 26) . Multiple trials of calcitriol using a variety of doses and schedules have been conducted. Daily and every-other-day schedules have been hindered by dose-limiting hypercalcemia (18) . Intermittent dosing (once weekly or daily for 3 consecutive days repeated every week) was not associated with any calcitriol DLTs (20, 27) . However, intermittent oral administration of the commercial oral formulations of calcitriol formulations was associated with limited bioavailability, considerable interpatient variability in AUC and C max , and loss of linear relationship between dose and exposure (AUC, C max ; refs. 20, 27) .
This phase I clinical trial is the first to investigate i.v. calcitriol escalation. The study was designed to identify the MTD dose of i.v. weekly calcitriol in combination with oral daily gefitinib based on previously described synergy data (16) . The MTD of i.v. calcitriol in combination with oral gefitinib (250 mg/d) was 74 Ag/wk. DLTs, in the form of hypercalcemia, were noted at 96 Ag/wk in two of four patients enrolled at that dose level. It is of interest that all patients with dose-limiting hypercalcemia on this study had head and neck cancers and suffered from cachexia, suggesting the possible susceptibility of this group of patients to hypercalcemia. Parathyroid hormone -related peptide (two patients) and parathyroid hormone (one patient) levels were slightly elevated in all DLT patients, but similar findings were also noted in other patients without hypercalcemia at various dose levels on this study. Thus, a paraneoplastic component of hypercalcemia in our DLT patients cannot be ruled out or confirmed at this point.
Gefitinib, with or without calcitriol, inhibited the skin EGFR pathway as measured by pEGFR, pErk, and pAkt. This is consistent with previously published data with single-agent gefitinib (28, 29) . However, a high degree of interpatient variability in staining limits the utility of this model. Furthermore, there was no correlation between pEGFR inhibition in the skin and tumor. This is highlighted by the lack of EGFR pathway inhibition in tumors of two patients who agreed to tumor biopsies (both had EGFR pathway inhibition in skin). This lack of tumor EGFR modulation by gefitinib plus calcitriol is in line with a recently reported phase II study of gefitinib in metastatic colorectal cancer in which neither the 250 nor 500 mg/d dose levels inhibited tumor EGFR pathway (30) . It is noteworthy that calcitriol did not positively modulate the effects of gefitinib on skin or tumor EGFR pathway. Amelioration of pAkt inhibition by gefitinib was observed in several patients. These results contrast with the preclinical data generated by our group in a preclinical squamous cell cancer model (16) . It is unclear if the lack of correlation between our clinical and preclinical data is due to inadequacy of skin as a surrogate marker for calcitriol activity or due to a divergence between preclinical and clinical effects of calcitriol. It is possible that intradermal concentrations of calcitriol, even at the higher dose levels, do not reach a threshold needed to exert biological activity. It is also possible that the variations made on the clinical schedule compared with the preclinical schedule may have affected the positive interaction between calcitriol and gefitinib that was documented in the laboratory. Finally, we cannot rule out that the timing of the skin and tumor biopsies (8 h after calcitriol dosing) may have failed to capture the effects of calcitriol on the EGFR pathway, especially that calcitriol C max was achieved f0.5 h after calcitriol administration.
Gefitinib did not affect the pharmacokinetics of calcitriol; pharmacokinetic variables were similar on days 1 (without gefitinib) and 15 (with gefitinib). The study design did not permit the evaluation of the effects of calcitriol on gefitinib. However, intensive gefitinib pharmacokinetic sampling on day 15 (day 8 of gefitinib) and trough levels (serum collected before a.m. dose) from day 22 of cycle 1 (day 15 of gefitinib) were consistent with steady-state levels from prior studies using single-agent gefitinib at 250 mg/d (e.g., on IDEAL 1 study; ref. 17) . 5 Thus, gefitinib pharmacokinetic data from this study are entirely consistent with historical gefitinib data. This suggests that there is no marked effect of calcitriol on gefitinib pharmacokinetics. However, given the high interpatient variability in the pharmacokinetics of gefitinib, it is unlikely that this type of comparison would rule out mild to moderate interactions. Calcitriol C max and AUC at the MTD (74 Ag/wk) were 6.68 F 1.42 ng/mL and 35.65 F 8.01 ng h/mL, respectively. It is surprising that C max and AUC were lower at the nontolerable calcitriol dose of 96 Ag/wk than the MTD. The lack of increase in AUC and C max at 96 Ag may be related to interpatient variability in calcitriol clearance or induction of calcitriol clearance at higher dose levels. The occurrence of DLT hypercalcemia at the 96 Ag dose level despite lower C max and AUC than the MTD could be related to patient selection at that dose level (cachectic with head and neck cancer). Other contributing factors in need of further investigation include variations in vitamin D receptor polymorphism, activity of metabolizing enzymes such as CYP24, and baseline calcium and vitamin D balance.
C max of calcitriol at the MTD (74 Ag/wk i.v.) was markedly higher than 10 nmol/L, the concentration associated with calcitriol single-agent activity in preclinical in vivo models (31, 32) . The C max of the MTD 74 Ag/wk i.v. calcitriol (6.68 ng/mL; C max 16 nmol/L) was also markedly higher than the C max achieved at 75 Ag of a novel weekly oral formulation of calcitriol (DN101, C max 3.8 nmol/L); however, AUC was similar for both formulations (35.6 and 38.4 for calcitriol and DN101, respectively; ref. 33) . C max achieved at our MTD of 74 Ag/wk i.v. calcitriol was comparable with the C max achieved with 165 Ag/wk of oral DN101 (33) . Higher C max levels with i.v. formulation of calcitriol compared with DN101 are expected given the longer T max of 1 to 2 h with DN101 in comparison with 0.5 h with i.v. calcitriol (achieved half way through infusion; ref. 33) . The lack of significant hypercalcemia at DN101 doses of 165 to 180 Ag/wk contrasts with the dose-limiting hypercalcemia noted in our study (33, 34) . It is unclear if the pharmacokinetic characteristics of i.v. administration versus oral administration may factor in this difference in hypercalcemic effects. It is possible that the higher C max levels in the presence of a threshold AUC have resulted in the higher hypercalcemic effects in our studies. This hypothesis will require further investigation in upcoming studies. Alternative explanations may be related to patient characteristics (such as parathyroid hormone or parathyroid hormone -related peptide baseline or primary tumor), especially that all DLT patients on our study were patients with head and neck cancer. We have shown the feasibility of safely administering high i.v. weekly doses of calcitriol up to 74 Ag in a refractory cancer population in combination with oral gefitinib. The lack of pharmacokinetic interaction with gefitinib suggests that similar doses of calcitriol can be administered as a single agent or in combination with other agents that have no pharmacokinetic interaction with calcitriol. For example, the investigation of high doses of i.v. calcitriol may be appealing in combination with taxanes, in which preclinical synergy has been established (35) . This is supported further by recent data that suggest a survival advantage to combining DN101 to docetaxel compared with docetaxel alone in patients with hormone refractory prostate cancer (36) . The formulation of i.v. calcitriol that is clinically available is a disadvantage (1 Ag/ampul). Ideally, further development of i.v. calcitriol should be accompanied by formulation of calcitriol in higher dose ampules.
The clinical development of high doses of calcitriol with chemotherapy continues to be under development in our institute based on favorable preclinical studies. No further clinical studies of calcitriol and gefitinib are planned given the withdrawal of gefitinib from the market and the lack of signs of activity in this large phase I study. Development of future calcitriol and anti-EGFR combinations should take into account the limitations of the skin pharmacodynamic model and should follow more extensive preclinical investigations.
